Abstract Adrenocorticotropic hormone (ACTH) is among several melanocortin peptide hormones that are derived from proopiomelanocortin (POMC). ACTH has been found to enhance osteogenesis and chondrogenesis. We show that, in the presence of dexamethasone, ACTH dose-dependently increases chondrogenic nodule formation in bone marrow stromal cells (BMSC) from the Wistar Kyoto (WKY) rat. The nodules consist in condensed cells highly expressing alkaline phosphatase, Sox9 and type II collagen transcripts and a proteoglycan-rich matrix. Immunoblot analysis of crude membrane fractions has shown that these cells express three melanocortin receptors (MC-R), namely MC2-R, MC3-R and MC5-R and the melanocortin 2-receptor accessory protein (MRAP). To determine which of these receptors mediate ACTH-induced effects, we have used MC-R-specific peptides and the known agonist profiles of the receptors. Neither α-MSH, a strong agonist of MC5-R, nor γ 2 -MSH, a strong agonist of MC3-R, duplicates ACTH effects in rat BMSC. In addition, calcium flux has been examined as a mechanism for ACTH action at the MC2-R. Consistent with MC2-R and MRAP expression patterns in the BMSC cultures, ACTH-induced transient increases in intracellular calcium are increased with dexamethasone treatment. Neither α-MSH nor γ 2 -MSH affects calcium flux. Dexamethasone increases MC2-R and MRAP expression and POMC peptide expression and cleavage increasing the production of the lipolytic β-lipotropic hormone product. Therefore, the effects of ACTH in rat BMSC enriched for mesenchymal progenitors are consistent with an MC2-R signaling mechanism, with dexamethasone being capable of regulating components of the melanocortin system in these cells.
Introduction
The precursor peptide proopiomelanocortin (POMC), derived from the pituitary gland and some peripheral tissues, is processed by tissue-specific prohormone convertases (PC) to produce the melanocortin peptides. Cleavage via PC1/3 produces ACTH and β-lipotropic hormone (β-LPH), whereas PC2 is required for the generation of α-melanocyte-stimulating hormone (α-MSH), β-MSH, γ-MSH and endorphins (Bicknell 2008; Catania 2007; Cone 2006) .
Melanocortin peptides signal through a family of five Gprotein-coupled receptors collectively termed MC-R.
Melanocortin peptides bind and activate MC-Rs with variable but specific affinities. The primary agonist of the MC1-R is α-MSH, the MC2-R is only responsive to ACTH, the primary agonist of the MC3-R is γ-MSH and the MC4-R and MC5-R bind to ACTH and α-MSH with equal affinities.
Ligand binding to the MC-R results in the activation of second messenger pathways, such as accumulation of adenylyl cyclase and the mobilization of intracellular calcium ([Ca 2+ ] i ); (Evans et al. 2005; Gallo-Payet and Payet 2003; Hoogduijn et al. 2002; Yang 2011) . Initiation of these second messenger effector pathways is largely dependent on which Gα-protein subunit is activated upon ligand binding to the receptor. Whereas activation of the Gα s subunit typically results in the activation of adenylyl cyclase and the accumulation of cAMP, the activation of the Gα q/11 family of subunits largely results in the mobilization of [Ca 2+ ] i (Neves et al. 2002) . MC-Rs are generally expressed in a tissue-specific manner. The MC1-R is primarily expressed in skin (Le Pape et al. 2008) , with more recent data demonstrating its expression in leukocytes (Getting et al. 2008; Kang et al. 2006) . The MC2-R is traditionally known to be expressed in the adrenal cortex (Chan et al. 2011; Papadimitriou and Priftis 2009) and in adipocytes (Noon et al. 2006) . The MC3-R and MC4-R are for the most part expressed in brain (Butler 2006; Cone 2006; Sutton et al. 2006 ) but there are reports of MC3-R expression in leukocytes (Getting et al. 2001 (Getting et al. , 2008 and chondrogenic cells (Evans et al. 2004 ) and of MC4-R expression in peripheral tissues (Mountjoy et al. 2003; Siljee-Wong 2011) . The MC5-R is the most ubiquitous and is highly expressed in exocrine tissues (van der Kraan et al. 1998; Zhang et al. 2011) .
All five MCRs are expressed by mesenchymal progenitors (Evans et al. 2004 (Evans et al. , 2005 (Evans et al. , 2012 Isales et al. 2010; Zaidi et al. 2010; Zhong et al. 2005) and previous in vitro studies have shown a direct relationship between their exposure to melanocortin peptides and their osteogenic and chondrogenic differentiation (Evans et al. 2004; Isales et al. 2010; Zaidi et al. 2010) . In this study, using osteogenic conditions, we have determined the effect of ACTH on proliferation, alkaline phosphatase expression and mineralization in rat bone-marrow-derived stromal cells (BMSC) enriched for mesenchymal progenitors. ACTH-induced calcium flux has been examined as a potential mechanism for ACTH effects in these cells. Additionally, we have determined the membrane-associated expression profile of the MC-R and the known peptide agonist profiles of the receptors have been used to determine the receptor that is responsible for mediating the ACTH signal. Dexamethasone is a synthetic glucocorticoid used to enhance mineralization in mesenchymal progenitor cultures and can promote chondrogenic differentiation of human mesenchymal stem cells (Derfoul et al. 2006; Pei et al. 2003) . Therefore, we have also examined the effect of dexamethasone on MC-R expression and calcium flux and on POMC and PC1/3 expression in our BMSC cultures.
Materials and methods

Materials
All cell culture media, trypsin, fetal bovine serum (FBS), charcoal/dextran-treated FBS and antibiotic/antimycotic solutions were obtained from Invitrogen (Carlsbad, Calif., USA). The integrinβ1, vimentin, fibronectin and MC-R polyclonal primary antibodies were from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). The POMC and PC1/3 antibodies were from Novus Biologicals (Littleton, Colo., USA). The melanocortin 2-receptor accessory protein (MRAP) antibody was from Protein Tech (Chicago, Ill., USA). The monoclonal Na + /K + ATPase α-1 antibody (clone C464.6) was from Millipore (Temeculae, Calif., USA) and the β-actin monoclonal antibody was from Sigma-Aldrich (USA). The α-MSH and γ 2 -MSH peptides were from BACHEM (Torrance, Calif., USA). The ACTH (1-39) porcine pituitary-derived peptide and all other chemicals were from Sigma-Aldrich (USA), unless otherwise specified.
Animals
All animal protocols were approved by the Institutions Animal Care and Use Committee and adhere to the regulations outlined by the National Institutes of Health. Wistar Kyoto (WKY) rats were obtained from Taconic, North America. Animals were housed under local vivarium conditions (12 h light-dark cycle) and allowed to acclimate for at least 7 days prior to experimentation. Rats were killed under CO 2 at 8-12 weeks of age and hind limbs were removed in preparation for bone marrow isolation.
Isolation of bone marrow stromal cells
Bone marrow from the hind limbs of the WKY rat was isolated as previously described (Yeh et al. 1999) . After the creation of a single-cell suspension, nucleated cells were counted by using 3% acetic acid/trypan blue exclusion and plated in α-MEM without phenol red but supplemented with 10% FBS, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B at 10 7 cells per 100-mm dish. Cultures were depleted of mature macrophage by 24 h adherence depletion. Non-adherent cells were then re-plated into 100-mm dishes and allowed to adhere for 3-4 days before the first medium change. The medium was changed every 2-3 days thereafter. At 80% confluence, cells were split at a ratio of 1:3 to 1:4. Cultures were used at passage 3 or 4.
Chondrogenic, adipogenic and osteogenic differentiation For chondrogenic differentiation, BMSC were plated as micromass culture and maintained in α-MEM without phenol red but supplemented with 5% charcoal/dextran-treated FBS, 50 μg/ml L-ascorbic acid, 40 μg/ml L-proline, 25 ng/ml bone morphogenetic protein-2, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B for 14 days prior to the staining of the proteoglycan-enriched matrix with Alcian blue. For adipogenic differentiation, confluent BMSC cultures were incubated in α-MEM without phenol red but supplemented with 10% FBS, 15 mM D-glucose, 1 μM dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine, 10 μg/ml insulin, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B for 4 days. The medium was then changed to a basal medium and cultures were incubated for 4 more days before being stained for neutral lipid accumulation by using Oil-Red-O. For osteogenic differentiation, confluent BMSC cultures were incubated in α-MEM without phenol red but supplemented with 10% FBS, 10 mM β-glycerophosphate, 50 μg/ml ascorbic acid, 10 −8 M dexamethasone, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B for 28 days before undergoing von Kossa staining for minerals.
Fluorescent immunocytochemistry BMSC at passage 3 or 4 were initiated in 8-well chamber slides at a density of 2,500 cells per well in basal medium. After 4 days of growth, cells were fixed in 2% paraformaldehyde, rinsed in phosphate-buffered saline (PBS) and blocked using 10% horse serum in PBS with 0.3% Triton X-100. Primary and appropriate secondary antibodies were diluted at 1:100 and 1:50, respectively, in a solution containing 1% bovine serum albumin (BSA), 1% horse serum, 0.3% Triton X-100 and 0.01% sodium azide. Normal goat IgG was used as a control. Washes were carried out with 0.1% BSA in PBS. Slides were mounted by using Vectashield mounting medium containing 4,6-diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame, Calif., USA).
Proliferation assay
Cell proliferation was assessed by using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were plated in basal medium at 7,500 cells per well in 96-well plates and treated with and without ACTH, α-MSH and γ 2 -MSH peptides at a range of doses (10 −6 M to 10 −8 M) for 1, 4 and 7 days. At each time point, MTT was added at 500 μg/ml and cultures were incubated for 3 h. Precipitated formazan was solubilized with 50% dimmethylsulfoxide in ethanol and the absorbance was read at 550 nm.
Alkaline phosphatase, proteoglycan matrix and mineral staining WKY BMSC cultures were established at a density of 2.5×10 4 cells per well in 24-well plates in α-MEM without phenol red but supplemented with 10% FBS, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B until near confluence. To induce mineralization, the medium was supplemented with 10 mM β-glycerophosphate, 50 μg/ml ascorbate acid and 10 −8 M dexamethasone. Melanocortin peptides were added with each medium change at a range of doses (10 −6 M to 10 −8 M). Cells were maintained in this medium for 14 days with changes every 2-3 days and peptides were added at every change. Alkaline phosphatase staining was carried out by using the Leukocyte Alkaline Phosphatase Kit from SigmaAldrich (85L2-KT) and following the manufacturer's instructions. To assess mineralization and proteoglycan matrix, cultures were fixed in 10% phosphate-buffered formalin and stained by using von Kossa stain or Alcian blue stain, respectively.
Real-time quantitative polymerase chain reaction Total RNA was extracted from WKY BMSC cultures maintained in α-MEM without phenol red but supplemented with 10% FBS, 10 mM β-glycerophosphate, 50 μg/ml ascorbate acid, 10 −8 M dexamethasone, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml after 4 or 9 days of treatment with or without 10 −7 M ACTH. Reverse transcription and the polymerase chain reaction (PCR) were carried out as described in Evans et al. (2009) . The primer sequences used were: type 1 collagen (Col1), 5′-AAG GCCCACGGGGACCTGTT-3′ and 5′-GGGCCAGGCAC GGAAACTCC-3′; type II collagen (Col2a1), 5′-CTACGG CGACGGCAACCTGG-3′ and 5′-TGCCCTCGGCCCT CATCTCC-3′; Sox9, 5′-GGGCGAGCACTCTGGGCAAT-3′ and 5′-CGTCGCGGAAGTCGATGGGG-3′; D-glyceraldehyde-3-phosphate dehydrogenase (Gapdh), 5′-GGGGCTCTCTGCTCCTCCTG-3′ and 5′-ACGGCAA AATCCGTTCACACCG-3′.
Immunoblotting
Crude membrane fractions were prepared from WKY BMSC. Cells were lysed in HES buffer (0.25 M sucrose, 5 mM EDTA, 2 mM EGTA, 20 mM HEPES) with 1× protease inhibitor cocktail (Sigma-Aldrich, USA; #P8340) and homogenized with a Teflon on glass homogenizer. The homogenate was then centrifuged at 760g for 5 min and the supernatant was centrifuged at 25,000 rpm for 1 h. The pellet was dissolved in modified RIPA buffer (50 mM TRIS-HCl, pH 7.4, 1% NP-40 (w/v), 0.25% Na-deoxycholate (w/v), 150 mM NaCl, 1 mM EDTA and 1× protease inhibitor cocktail) and the protein content was determined via bicinchroninic acid assay (BCA) (Thermo Fisher Scientific). To normalize for protein loading, membrane fractions were also probed for Na + /K + ATPase expression. Whole lysates were prepared from BMSC cultures that had either been left untreated or treated with dexamethasone for 2 or 5 days. Protein concentrations were determined by BCA assay. Protein samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene membrane. After being blocked, membranes were incubated with either POMC or PC1/3 primary antibodies. Following incubation with an appropriate horseradish peroxidase (HRP)-tagged secondary antibody, bands were visualized by using enhanced chemiluminescence. To normalize protein loading, blots were also probed for β-actin expression.
Calcium measurements
Transient elevations in calcium in response to melanocortin peptides were measured as previously described (Evans et al. 2005) . Briefly, at confluence, WKY BMSC cultures were incubated in α-MEM supplemented with 5% charcoal/dextran-treated FBS, 100 U/ml penicillin sodium, 100 U/ml streptomycin sulfate and 0.25 μg/ml amphotericin B. Cultures were maintained in this medium for at least 5-7 days. Before assay, some cultures were treated with 10 −8 M dexamethasone for at least 48 h. Single-cell suspensions were created by using trypsin and collagenase, centrifuged and re-suspended in calcium loading buffer with Ca 2+ (Hank's balanced salt solution plus Ca 2+ and Mg 2+ supplemented with 0.05% BSA) and loaded with 1.5 mM fura-2 at room temperature. For measurements made in the absence of extracellular calcium, calcium loading buffer without Ca 2+ (Hank's balanced salt solution without Ca 2+ and Mg 2+ supplemented with 0.05% BSA and 80 mM MgCl) was used. All peptides were first diluted in sterile water at a stock concentration of 5 mM and stored in small aliquots at −20°C. On the day of use, stocks were further diluted by 10× and 100× in calcium loading buffer without Ca 2+ and used in experiments at the concentrations stated in the text.
Statistical analysis
Data were analyzed using one-way analysis of variance (ANOVA) or two-way ANOVA where indicated. Post hoctest P-values were adjusted by using the Bonferroni correction. All tests were two-tailed and a nominal significance level of 0.05 was used.
Results
Third and fourth passage rat BMSC are capable of multi-lineage differentiation BMSC were isolated from the hind limbs of Wistar Kyoto rats and enriched for mesenchymal progenitors. After isolation, cells were first depleted of mature macrophages through a 24-h adherence depletion. The 24-h nonadherent cells were subsequently plated and passaged 3 to 4 times to deplete the cultures of leukocytes and mature cells of the mesenchymal lineage. To establish the mesenchymal progenitor potential of our cultures, we tested their ability to differentiate into multiple lineages. After adipogenic induction, BMSC enriched for mesenchymal progenitors accumulated lipid as assessed by oil-red-O stain; after chondrogenic induction, they formed Alcian-blue-positive colonies; and after osteogenic induction, they were mineralized consistent with osteogenic differentiation (Fig. 1a-c) .
To determine the homogeneity of the enriched BMSC cultures, we examined the expression of the mesenchymal cell markers integrinβ1, fibronectin and vimentin by using fluorescent immunocytochemistry. The cultures were 96% positive for integrinβ1, 98% positive for vimentin and 90% positive for fibronectin, respectively ( Fig. 1d-f ).
Rat BMSC enriched for mesenchymal progenitors express MC2-R and its accessory protein MRAP, plus MC3-R and MC5-R; expression of MC2-R and MRAP is regulated by dexamethasone Several groups have described the gene and protein expression of MC-R in progenitor cell populations (Evans et al. 2004 (Evans et al. , 2005 Isales et al. 2010; Zaidi et al. 2010; Zhong et al. 2005) . We used crude membrane preparations to confirm that the MC-R expressed by mesenchymal-progenitorenriched BMSC were membrane-associated and therefore functional. We also determined whether glucocorticoid regulated their expression. Cultures were left untreated or treated with 10 −8 M dexamethasone for 48 h. Enriched rat BMSC expressed the MC2-R, MC3-R and MC5-R. The MC4-R was not detected (data not shown).
No notable changes in MC3-R and MC5-R expression occurred on dexamethasone treatment (Fig. 2c, d) . However, the expression of the MC2-R was up-regulated by treatment with dexamethasone (Fig. 2a) . The MC2-R was expressed as its 33-kDa immature and 50-kDa mature forms and the expression of both was increased with dexamethasone treatment.
Recent data have revealed that the MC2-R requires the MC2-R accessory protein (MRAP) to reach the cell surface (Sebag and Hinkle 2007; Webb and Clark 2010) . Therefore, we examined the expression of MRAP in membrane fractions of rat BMSC to confirm MC2-R cell surface expression and function. MRAP was detected as a 14-kDa band and increased with dexamethasone treatment (Fig. 2b) .
ACTH increases proliferation in rat BMSC enriched for mesenchymal progenitors in a manner dependent on dose; α-MSH and γ-MSH do not duplicate this effect
The MTT assay was used to determine the effects of ACTH treatment on cell proliferation in BMSC cultures. By day 7, ACTH increased proliferation in a manner consistent with increasing dose (Fig. 3a) ; proliferation in the BMSC cultures was increased by 5.65% at 10 −8 M, 11.35% at 10 −7 M and 15.4% at 10 −6 M ACTH. Results of two-way ANOVA, with the time and dose of ACTH as factors, demonstrated a s i g n i f i c a n t i n t e r a c t i o n e f f e c t [ F ( 6 , 8 4 ) = 6 1 . 5 3 , P<0.0001]. These data confirmed an increase in proliferation with increasing ACTH dose over time.
Results of proliferation assays with γ 2 -MSH, a primary agonist of the MC3-R and α-MSH, a primary agonist of the MC5-R did not show a significant proliferation effect and did not duplicate the pattern observed when BMSC were treated with ACTH (Fig. 3b, c) . Previous studies have demonstrated an ACTH effect on chondrogenic differentiation (Evans et al. 2004 ) and on osteogenesis and mineralization in human mesenchymal stem cell cultures . Here, we demonstrate that ACTH dose-dependently increases the formation of mineralizing nodule formation (Fig. 4) in rat BMSC enriched for mesenchymal progenitors when grown under typical osteogenic conditions for 14 days. The mineralizing nodules consisted in condensed mesenchymal cells consistent with a chondrogenic differentiation program. The nodules were also highly positive for alkaline phosphatase and resided in a proteoglycanrich matrix (Fig. 4a-o) . One way ANOVA results revealed a significant ACTH dose effect on nodule formation, P<0.0001 and as with the proliferation study, treatment with γ2-MSH or α-MSH did not duplicate ACTH effects (Fig. 4p-r) .
ACTH increases early gene markers of mesenchymal progenitor chondrogenic differentiation Alkaline phosphatase and mineralization are both late markers of mesenchymal progenitor cell differentiation along the chondrogenic pathway (Minashima et al. 2012 ) but can also indicate osteogenic differentiation.
To confirm that the ACTH-induced increase in mineralizing nodules reflected an increase in chondrogenic differentiation, we examined the expression of the Sox9 chondrogenic transcription factor and the early marker of chondrogenic differentiation, type II collagen (Col2a1). ACTH increases the expression of the Sox9 transcription factor by 1.25-fold at day 4 and by 1.42-fold at day 9 of culture. Expression of Col2a1 is also increased by ACTH exposure by 1.80-fold at day 4 and by 1.54-fold at day 9 (Fig. 5) . . MC-Rs and MRAP were detected by immunoblot in crude membrane fraction lysates (50 μg per lane). Na/K ATPase was used to normalize loading (asterisk non-specific band) Fig. 3 Adrenocorticotropic hormone (ACTH) promotes cell proliferation of rat BMSC enriched for mesenchymal progenitors in a dosedependent manner (a). γ 2 -Melanocyte-stimulating hormone (γ 2 -MSH; b) and α-melanocyte-stimulating hormone (α-MSH; c) do not exhibit this effect. Proliferation in response to melanocortin peptides was assessed by using MTT assay. The fold change in the optical density of the formazan product from 24 h post-plating (day 0) is shown. Data are presented as means ± SD, n=8. Data are representative of three separate experiments with similar results. Individual comparisons were made after a significant two-way ANOVA (day × ACTH dose) by using the Bonferroni correction. ACTH promotes chondrogenic mineralized nodule formation, in a dose-dependent manner, in rat BMSC enriched for mesenchymal progenitors. γ 2 -MSH and α-MSH do not exhibit this effect. Cultures were stained for minerals (a-d), for alkaline phosphatase (e-h), or for a proteoglycan matrix (i-k) after 14 days of osteogenic culture in the presence or absence of ACTH at a range of doses (10 −8 to 10 −6 M). Photomicrographs were taken under bright field and scanning power (40× total magnification) to emphasize differences in nodule numbers with ACTH treatment. Bars500 μM. Photomicrographs in m-o were taken by using bright field (200× total magnification) in order to emphasize the multi-cellular alkaline phosphatase (m), rich proteoglycan (n), mineralizing nodules (o) and condensed cells in the periphery (arrowheads condensed cells in the periphery of the nodules and chondrocytes in lacunae). Bar100 μM. In p-r, the number of mineralized nodules per well in ACTH-treated cultures and α-MSH and γ 2 -MSH cultures are presented as a percentage of the untreated control (0) ± SEM. Data are representative of three separate experiments with each treatment group having n=3-5 wells. Individual comparisons were made after a significant oneway ANOVA by using the Bonferroni correction. Melanocortin peptides are known to initiate both the cAMPand Ca 2+ -mediated second-messenger pathways. In chondrogenic cells, ACTH induces calcium flux in a phospholipase-C-dependent manner (Evans et al. 2005) . Therefore, in order to delineate possible intracellular pathways that were activated by ACTH in rat BMSC, we used the fluorescent Ca 2+ indicator, fura-2, to examine intracellular Ca 2+ flux. In the presence of extracellular Ca 2+ , ACTH induced transient increases in [Ca 2+ ] i in a manner dependent on the dose. These transient elevations increased when the cells are primed with dexamethasone (Fig. 6a, b, e) . Results of two-way ANOVA revealed a significant dose effect of ACTH [F (2,12) =111.68, P=0.0001] and dexamethasone priming [F (1,12) =13.14, P=0.0035]. Neither γ2-MSH nor α-MSH induced transient elevations in [Ca 2+ ] i in untreated or dexamethasone-treated rat BMSC (Fig. 6g-j) .
To determine the source of the Ca 2+ during the ACTHinduced transient increase in [Ca 2+ ] i , we examined Ca 2+ flux in the absence of calcium. When cells were exposed to ACTH over a range of doses (10 −8 M to 10 −6 M) in the absence of extracellular Ca 2+ , no substantial changes in [Ca 2+ ] i were observed. When Ca 2+ was added back to the medium at 3 min after stimulation with ACTH, transient increases of [Ca 2+ ] i were consistent with increasing dose of ACTH (Fig. 6c, f) . Treatment with dexamethasone increased the ACTH-induced Ca 2+ influx above that observed in untreated control cultures (Fig. 6d-f Dexamethasone regulates POMC and PC1/3 expression in rat BMSC enriched for mesenchymal progenitors POMC and PC1/3 are expressed in peripheral tissues (Bicknell 2008; Harbour et al. 1987; Rajora et al. 1996; Star et al. 1995) and dexamethasone is used to enhance mineralization during osteogenic differentiation of progenitor cells (Bruedigam et al. 2011; Mostafa et al. 2011) . Dexamethasone also promotes chondrogenic differentiation of human mesenchymal stem cells (Derfoul et al. 2006) . Therefore, we examined the expression of POMC and PC1/3 in rat BMSC and the effects of dexamethasone on these proteins. POMC, its derivatives and the POMC cleavage enzyme PC1/3 were expressed in rat BMSC (Fig. 7) . PC1/3 was expressed as its inactive 97-kDa form and its partially active 84-kDa form. After 2 and 5 days of dexamethasone treatment, the expression of POMC was increased 1.43-fold and 1.25-fold, respectively. Expression of the 97-kDa form of PC1/3 was increased 1.49-fold and 1.25-fold, respectively, whereas the expression of the 84-kDa form was increased by 1.93-fold and 1.29-fold, respectively (Fig. 7a) .
If the expression of PC1/3 was indeed increased, then we expected this to be reflected in increased processing of the POMC precursor. Therefore, we also examined the level of the β-LPH cleavage product after cells were treated with dexamethasone. Using a 15% PAGE gel and the same POMC antibody that detects the Cterminal epitope of POMC, we were able to determine that β-LPH (∼10 kDa) levels increased with exposure to dexamethasone, consistent with increased PC1/3 activity (Fig. 7b) . After 5 days of treatment with 10 −8 M or 10 −7 M dexamethasone, β-LPH expression increased by 1.34-fold and 1.92-fold, respectively.
Discussion
Previous work has introduced the presence of a local melanocortin system in bone and cartilage (Evans et al. 2004; Isales et al. 2010; Zaidi et al. 2010; Zhong et al. 2005) . These studies have documented gene and protein expression of the MC2-R and other MC-R in human bone and mesenchymal cells and in mouse bone tissues Zhong et al. 2005) . In this work, we have detected the MC2-R, MC3-R and MC5-R proteins in membrane fractions of rat BMSC enriched for mesenchymal progenitors suggesting that these receptors are functional in these cells. ACTH, a potent agonist at all three of these receptors, enhances chondrogenic mineralizing nodule formation of our mesenchymal progenitor-enriched BMSC cell population in a dosedependent manner. Therefore, we have sought to identify the MC-R through which ACTH exerts these effects in these cells. We present evidence that identify the MC2-R as the mediator of ACTH-induced effects in rat BMSC. Neither γ 2 -MSH, a potent MC3-R agonist, nor α-MSH, a potent MC5-R agonist, duplicates the effects of ACTH. The MC2-R accessory protein is also expressed in rat BMSC Fig. 6 ACTH induces transient elevations in [Ca 2+ ] i through an influx of extracellular calcium in rat BMSC enriched for mesenchymal progenitors. This influx is enhanced with dexamethasone priming. In the presence of extracellular calcium (+EC Ca 2+ ), ACTH induces transient increases in [Ca 2+ ] i in a manner consistent with the dose in BMSC left untreated (a, e). When rat mesenchymal stem cells are treated with 10 −8 M dexamethasone for 48 h (+Dex), these increases are enhanced (b, e). Some cultures, left untreated (c, f) or treated with 10 −8 M dexamethasone (d, f), were re-suspended in buffer without Ca 2+ and exposed to ACTH over a range of doses (10 −8 M to 10 −6 M). After ∼3 min, Ca 2+ (1.8 mM) was added back to the medium and Ca 2+ influx was measured. Times of Ca 2+ addition are indicated by the lines above the traces. The dose of ACTH in moles per liter is indicated under or next to the corresponding trace. In e, f, the results shown in a-d are presented as bar graphs and indicate the Δ in [Ca 2+ ] i from the baseline. Data are presented as means ± SD, n=3. Individual comparisons were made after a significant two-way ANOVA by using the Bonferroni correction. *Significantly different from the dexamethasone-treated counterpart. Neither α-MSH (10 −6 M) nor γ 2 -MSH (10 −6 M) elicit changes in [Ca 2+ ] i in the untreated control (g, i) or dexamethasone-treated (h, j) cultures (arrows time of ACTH, α-MSH, or γ 2 -MSH addition). α-MSH or γ 2 -MSH were added at 10 −6 M. Traces are representative of three separate experiments confirming the capacity for MC2-R cell surface expression and function. Moreover, results of MC2-R expression studies and calcium flux studies are consistent; dexamethasone treatment up-regulates MC2-R expression and increases ACTH-induced calcium flux. Again, neither γ 2 -MSH nor α-MSH have an effect on [Ca 2+ ] i in these cells. More studies are necessary to delineate the MC2-R pathway fully and to determine the role(s) of the MC3-R and MC5-R in these cells.
ACTH is known to increase the proliferation of BMSC as measured by 3 H-thymidine incorporation (Evans et al. 2004) and in the present study, we confirm this effect and show its dependence on dose by measuring mitochondrial activity (Fig. 3) . Additionally, previous studies have demonstrated that, under chondrogenic conditions, ACTH enhances the development of the chondrogenic phenotype among rat BMSC (Evans et al. 2004) , whereas other data show that ACTH enhances osteoblast development in murine-derived BMSC ). In the current study, rat BMSC have been exposed to ACTH under osteogenic conditions with the inclusion in dexamethasone. Under these conditions, ACTH increases the development of mineralizing nodules consistent with chondrogenic differentiation. The nodules consist in condensed mesenchymal cells, an essential step in chondrogenic differentiation (Ghosh et al. 2009 ). They are also positive for alkaline phosphatase and a proteoglycan-rich matrix consistent with terminally differentiating chondrocytes (Minashima et al. 2012) . Moreover, ACTH increases the expression of the chondrogenic transcription factor, Sox9 and the early chondrocyte marker gene, Col21a. Thus, our results indicate that, under typical osteogenic conditions, ACTH promotes a chondrogenic phenotype in rat BMSC.
The discrepancy between this study and the study that reveals ACTH as an osteogenic facilitator ) is likely to be attributable to species differences and/or the presence of dexamethasone in the cultures. There can be significant variation in bone marrow composition between species of animals (Elmore 2006 ) and this could easily lead to differences in the progenitor potential of isolated stromal populations. Additionally, the studies of mouse bone marrow were performed in the absence of dexamethasone and ACTH-induced enhanced osteogenic differentiation was only observed during the latest stages of differentiation . Our rat BMSC cultures were grown in the presence of dexamethasone, which has been shown to promote chondrogenic differentiation in human mesenchymal stem cell cultures (Derfoul et al. 2006) . Under these conditions, ACTH-induced increases in nodule formation can be observed by using light microscopy as early as 9 days post-treatment.
The MC-Rs belong to a family of G-protein-coupled receptors and activate both Gα s and Gα q proteins traditionally resulting in increased cAMP accumulation or transient fluxes in [Ca 2+ ] i , respectively (Evans et al. 2005; GalloPayet and Payet 2003; Hoogduijn et al. 2002) . Factors that increase the differentiation of both chondrocytes and osteoblasts from progenitors also increase [Ca 2+ ] i (Shin et al. 2008; Sun et al. 2007; Wang et al. 1998; Zayzafoon 2006) . Indeed, calcium-ionophore-induced elevations in [Ca 2+ ] i can promote chondrogenesis though a calcineurin/nuclear factor of activated T-cells axis (Tomita et al. 2002) . Therefore, we investigated the ability of ACTH to induce transient elevations in [Ca 2+ ] i and to raise basal [Ca 2+ ] i in rat BMSC, an ability that would provide a mechanism for ACTH effects. In these cells, ACTH induced transient elevations in [Ca 2+ ] i through an influx of extracellular Ca 2+ . Fig. 7 Dexamethasone increases the expression of proopiomelanocortin (POMC), prohormone convertase 1/3 (PC1/3) and the POMC cleavage product, β-lipotropic hormone (LPH), in rat BMSC cultures enriched for mesenchymal progenitors. In a, cultures were left untreated (−) or were treated with 10 −8 M dexamethasone (+Dex) for 2 and 5 days. Protein lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE; 50 μg/lane). β-actin was used to normalize loading. Densitometry measurements are indicated below the corresponding lanes. Band intensities were normalized to the loading control and are presented as the fold change from the untreated (−) cultures. In b, whole protein lysates were prepared from cultures untreated (−) or treated with 10 −8 M or 10 −7 M dexamethasone and subjected to SDS-PAGE (30 μg/lane). β-Actin was used to normalize loading. Densitometry measurements are indicated below the corresponding lanes. Band intensities were normalized to the loading control and are presented as the fold change from the untreated (−) cultures
No appreciable transient increases of calcium were observed in the absence of extracellular Ca 2+ . The extracellular influx in rat BMSC, through activation of the MC2-R, thus appears to be a receptor-operated calcium-entry mechanism. These data contrast with previous work with committed chondroprogenitor populations and aorta-derived mesenchymal progenitor populations in which ACTH induces the mobilization of calcium from intracellular stores and the influx of extracellular calcium (Evans et al. 2005 (Evans et al. , 2012 . As cells differentiate, basal cytosolic calcium and calcium in intracellular stores increase. The handling of those stores in response to ACTH stimulation probably varies according to lineage commitment and to stage of differentiation. Notably, ACTH-induced changes in [Ca 2+ ] i were measured in trypsindetached suspended progenitor-enriched BMSC cultures and the effects of this treatment must be considered. More studies examining this effect in adherent cultures are therefore warranted.
Dexamethasone is often used to promote mineral accumulation in mesenchymal progenitor cultures (Bruedigam et al. 2011; Mostafa et al. 2011) . The mechanisms through which dexamethasone promotes chondrogenic and osteogenic differentiation and mineralization are still being investigated. In osteogenesis, some data suggest that dexamethasone upregulates osteoblast-specific transcription factors such as Cbfa1 and Osterix (Igarashi et al. 2004; Mikami et al. 2011) , whereas others have found that it can also up-regulate chondrogenic transcription factors such as Sox-9 (Derfoul et al. 2006) . Our data suggest that dexamethasone can also influence osteogenic/chondrogenic differentiation and mineralization in culture through the regulation of the melanocortin system. Dexamethasone increases the expression of the MC2-R, the melanocortin pre-cursor peptide, POMC and the POMC cleavage enzyme, PC1/3. Activity of the PC1/3 enzyme is also increased as evidenced by the increase in the β-LPH cleavage product. β-LPH is a known lipolytic (Halabe Bucay 2008) and therefore, its up-regulation in response to dexamethasone exposure is fitting, as glucocorticoids are known to mobilize lipid. The possibility exists that, through the local up-regulation of β-LPH, dexamethasone promotes the lypolysis of adipogenic cells in BMSC, thereby favoring osteogenic/chondrogenic differentiation. Although our cultures are enriched for mesenchymal progenitors, the precise cell type expressing β-LPH is yet to be determined. Our cultures were significantly homogeneous for mesenchymal markers pointing to the likely expression by mesenchymal cells but their precise developmental stage and lineage commitment needs to be clarified.
Some have hypothesized that β-LPH supports hematopoietic stem cells by mobilizing local adipocytic energy reserves (Halabe Bucay 2008) and the pituitary has thus far been considered as the major source of β-LPH. Here, we present evidence that this hormone is probably produced locally by cells of the bone marrow and potentially participates in the release of lipids. The peripheral expression of POMC peptides is not unprecedented. We have detected the expression of POMC and of PC1/3 in mesenchymal progenitors derived from mouse aorta (Evans et al. 2012 ) and immune cells produce α-MSH and ACTH (Harbour et al. 1987; Rajora et al. 1996; Star et al. 1995) . Moreover, recent data demonstrate β-LPH expression in many tissues and its localization in peroxisomes (Hoftberger et al. 2010) . However, there is little data regarding the function of β-LPH beyond its capacity for lipid mobilization. The receptor mediating β-LPH actions is also not clearly defined, although the MC5-R is a potential candidate (Boston 1999) . More studies are needed to explore the paracrine roles of these peptides in tissues outside of the central nevous system and to define fully their receptors and the pathways that they mediate.
The present study demonstrates that, under typical osteogenic culture conditions, exposure to ACTH enhances the development of mineralizing chondrogenic nodules in rat BMSC cultures enriched for mesenchymal stem cells. ACTH also initiates a MC2-R-mediated pathway that induces transient increases in [Ca 2+ ] i and elevates basal [Ca 2+ ] i in these cells. Additionally, dexamethasone can regulate components of this pathway, namely the expression of the MC2-R and its accessory protein, MRAP and the cleavage of the POMC precursor to produce β-LPH. These data provide further evidence for an active local melanocortin system in bone and cartilage.
